PCSK9 and fatty liver disease: In addition to a reduction in diet-induced hepatic steatosis and adiposity, Our results also show that in addition to its hepato-protective effect, the ME improved a pro-atherogenic serum profile by lowering circulating PCSK9 and ApoB.